A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Cambios precancerosos del cuello uterino; Neoplasia intraepitelial cervical (NIC)
El tratamiento depende del grado de la displasia. La displasia leve (LEIBG o NIC I) puede desaparecer en forma espontánea.
El tratamiento para la displasia de moderada a grave o la displasia leve que no desaparece puede abarcar:
En raras ocasiones, se puede necesitar una histerectomía. Las mujeres a quienes se les trata la displasia necesitan un control constante, generalmente cada 3 a 6 meses o como se los recomiende el médico.
Casi todos los casos de displasia cervical se curan con un diagnóstico temprano y un tratamiento oportuno. Algunas veces, la afección reaparece.
Sin tratamiento, la displasia cervical grave puede convertirse en cáncer invasivo. Pueden pasar 10 años o más para que la displasia cervical se convierta en cáncer. El riesgo de cáncer es más bajo para la displasia leve.
Solicite una cita con su médico si usted tiene 21 años o más y nunca antes le han hecho un examen pélvico ni una citología vaginal.
Cervical cancer in adolescents: screening, evaluation, and manage- ment. Committee Opinion No. 463. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2010;116:469–72.
ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. 2008;112(6):1419-1444.
Wright TC Jr, Massad LS, Dunton CJ, et al. American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcihnoma in situ. Am J Obstet Gynecol. 2007;197(4):340-345.
Wright TC Jr, Massad LS, Dunton CJ, et al. American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346-355.
Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361:271-278.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.800.492.5538